## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.42 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($168.97)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Voya Investment Management LLC Reduces Stock Holdings in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251221T122101 | Neutral | Relevance: 100%
- Voya Investment Management LLC significantly reduced its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 62.0% in the third quarter, selling over 250,000 shares. Despite this, other institutional investors like Norges Bank, M&G PLC, and Boston Partners increased their holdings. Insider selling also occurred, while Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $197.27 for DGX.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 6 ($3.55M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.7% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.5M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.42 suggests fair value with growth premium. Forward P/E 16.9x stretched relative to 6% growth. Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.6B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.42 |
| Forward P/E | 16.9 |
| Current P/E | 17.8 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.0% to -4.7% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.7pp (needs >4.0% for momentum thesis). AM_20 at -3.7% indicates price below own 20MA trend. Underperforming sector by 4.4pp, stock-specific weakness. Below SMA200 (0.99x), long-term trend not supportive. MACD histogram bearish (-0.85), momentum weakening. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.71% (CS: 13) | Weak |
| RSI_14 | 35.3 | Neutral |
| MACD Histogram | -0.85 | Bearish |
| vs SMA20 | 0.963x | Below |
| vs SMA50 | 0.957x | Below |
| vs SMA200 | 0.988x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $175.07
- **Stop Loss:** $168.97 (3.5% risk)
- **Target:** $187.27 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 196
- **Position Value:** $34,313.72
- **Portfolio %:** 34.31%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*